Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ENCODE Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Developing Fast Pediatric Imaging

NCT03761121
View directory record Official record
Conditions
Pediatric Low-grade Gliomas
Interventions
Wave-CAIPI
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

NCT02705196
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
delolimogene mupadenorepvec, gemcitabine, nab-paclitaxel, atezolizumab
Genetic · Drug · Biological
Lead sponsor
Lokon Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Improving Response to Intervention in Students With or at Risk of Reading Disabilities

NCT03261661
View directory record Official record
Conditions
Reading Problem
Interventions
Reading, Mindset, Reading Embedded with Mindset, Business as Usual
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
9 Years to 11 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 5, 2026, 2:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy for Haemophilia A.

NCT03001830
View directory record Official record
Conditions
Hemophilia A
Interventions
AAV2/8-HLP-FVIII-V3
Biological
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
3
States / cities
Boise, Idaho • Lexington, Kentucky • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Correcting Residual Errors With Spectral, Ultrasound, Traditional Speech Therapy

NCT03737318
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Biofeedback-ultrasound, Biofeedback--visual-acoustic, Traditional articulation treatment
Behavioral
Lead sponsor
New York University
Other
Eligibility
9 Years to 15 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
Bloomfield, New Jersey • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

NCT04483440
View directory record Official record
Conditions
Choroideremia
Interventions
4D-110
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 5, 2026, 2:05 AM EDT
Terminated Phase 3 Interventional Results available

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

NCT03495921
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 5, 2026, 2:05 AM EDT
Completed No phase listed Observational

Enhancing Motor Task Training by Action Observation Watching Others Perform the Task

NCT00393432
View directory record Official record
Conditions
Motor Memory
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria

NCT00870987
View directory record Official record
Conditions
Malaria
Interventions
DNA vaccine prime, adenovirus type 5 vaccine boost
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 5, 2026, 2:05 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Computer-based Training of Face Recollection to Improve Face Recognition in Developmental Prosopagnosia

NCT04799340
View directory record Official record
Conditions
Developmental Prosopagnosia
Interventions
cognitive training
Behavioral
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 5, 2026, 2:05 AM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access of Vigil in Solid Tumors

NCT03842865
View directory record Official record
Conditions
Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Vigil
Biological
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

NCT03584165
View directory record Official record
Conditions
Choroideremia, X-Linked Retinitis Pigmentosa
Interventions
BIIB111, BIIB112
Genetic
Lead sponsor
NightstaRx Ltd, a Biogen Company
Other
Eligibility
18 Years and older · Male only
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT00450814
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Pharmacological Study
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

NCT03171493
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
MV-NIS
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Miami, Florida • New Orleans, Louisiana • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 5, 2026, 2:05 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

NCT04213261
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Completed No phase listed Observational Results available

Pediatric Language and Memory Mapping in Refractory Epilepsy Using Magnetoencephalography

NCT04888637
View directory record Official record
Conditions
Epilepsy
Interventions
Baseline MEG Test, Receptive Language Task, Memory Task
Diagnostic Test · Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
8 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Results available

Comparing Traditional and Biofeedback Telepractice Treatment for Residual Speech Errors

NCT04625062
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Visual-acoustic biofeedback, Motor-based treatment
Behavioral
Lead sponsor
New York University
Other
Eligibility
9 Years to 15 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bloomfield, New Jersey • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 5, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00010127
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 5, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

NCT03439085
View directory record Official record
Conditions
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
Interventions
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987
View directory record Official record
Conditions
HIV Infections
Interventions
TriGrid™ Delivery System, conventional intramuscular injection
Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 5, 2026, 2:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Encoding for Memory

NCT00051870
View directory record Official record
Conditions
Healthy
Interventions
Magstim Rapid Magnetic Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 2:05 AM EDT
Enrolling by invitation Not applicable Interventional

Intracranial EEG to Test How Noninvasive Stimulation Affects Hippocampal-dependent Memory

NCT07397897
View directory record Official record
Conditions
Memory Performance, Hippocampal Network Activity
Interventions
Transcranial magnetic stimulation (TMS)
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Completed No phase listed Observational

Studying Tumor Samples From Young Patients With Neuroblastoma

NCT00907920
View directory record Official record
Conditions
Neuroblastoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 5, 2026, 2:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Testing Native Language Neural Commitment at the Subcortical Level

NCT02774356
View directory record Official record
Conditions
Language Development
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 5, 2026, 2:05 AM EDT